176 related articles for article (PubMed ID: 31074257)
21. Size-Optimized Ultrasmall Porous Silica Nanoparticles Depict Vasculature-Based Differential Targeting in Triple Negative Breast Cancer.
Goel S; Ferreira CA; Dogra P; Yu B; Kutyreff CJ; Siamof CM; Engle JW; Barnhart TE; Cristini V; Wang Z; Cai W
Small; 2019 Nov; 15(46):e1903747. PubMed ID: 31565854
[TBL] [Abstract][Full Text] [Related]
22. CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer.
Wang Z; Sau S; Alsaab HO; Iyer AK
Nanomedicine; 2018 Jun; 14(4):1441-1454. PubMed ID: 29678787
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography (PET) guided glioblastoma targeting by a fullerene-based nanoplatform with fast renal clearance.
Peng Y; Yang D; Lu W; Hu X; Hong H; Cai T
Acta Biomater; 2017 Oct; 61():193-203. PubMed ID: 28801268
[TBL] [Abstract][Full Text] [Related]
24. On-Demand Biodegradable Boron Nitride Nanoparticles for Treating Triple Negative Breast Cancer with Boron Neutron Capture Therapy.
Li L; Li J; Shi Y; Du P; Zhang Z; Liu T; Zhang R; Liu Z
ACS Nano; 2019 Dec; 13(12):13843-13852. PubMed ID: 31697475
[TBL] [Abstract][Full Text] [Related]
25. ⁶⁴Cu-Doped PdCu@Au Tripods: A Multifunctional Nanomaterial for Positron Emission Tomography and Image-Guided Photothermal Cancer Treatment.
Pang B; Zhao Y; Luehmann H; Yang X; Detering L; You M; Zhang C; Zhang L; Li ZY; Ren Q; Liu Y; Xia Y
ACS Nano; 2016 Mar; 10(3):3121-31. PubMed ID: 26824412
[TBL] [Abstract][Full Text] [Related]
26. In Vivo Targeting and Positron Emission Tomography Imaging of Tumor with Intrinsically Radioactive Metal-Organic Frameworks Nanomaterials.
Chen D; Yang D; Dougherty CA; Lu W; Wu H; He X; Cai T; Van Dort ME; Ross BD; Hong H
ACS Nano; 2017 Apr; 11(4):4315-4327. PubMed ID: 28345871
[TBL] [Abstract][Full Text] [Related]
27. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
[TBL] [Abstract][Full Text] [Related]
28.
Lee H; Shields AF; Siegel BA; Miller KD; Krop I; Ma CX; LoRusso PM; Munster PN; Campbell K; Gaddy DF; Leonard SC; Geretti E; Blocker SJ; Kirpotin DB; Moyo V; Wickham TJ; Hendriks BS
Clin Cancer Res; 2017 Aug; 23(15):4190-4202. PubMed ID: 28298546
[No Abstract] [Full Text] [Related]
29. Folate Receptor α-Targeted
Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
Guo P; Yang J; Huang J; Auguste DT; Moses MA
Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668
[TBL] [Abstract][Full Text] [Related]
31. Companion Diagnostic
Lee H; Gaddy D; Ventura M; Bernards N; de Souza R; Kirpotin D; Wickham T; Fitzgerald J; Zheng J; Hendriks BS
Theranostics; 2018; 8(9):2300-2312. PubMed ID: 29721081
[TBL] [Abstract][Full Text] [Related]
32. Facile method to radiolabel glycol chitosan nanoparticles with (64)Cu via copper-free click chemistry for MicroPET imaging.
Lee DE; Na JH; Lee S; Kang CM; Kim HN; Han SJ; Kim H; Choe YS; Jung KH; Lee KC; Choi K; Kwon IC; Jeong SY; Lee KH; Kim K
Mol Pharm; 2013 Jun; 10(6):2190-8. PubMed ID: 23586421
[TBL] [Abstract][Full Text] [Related]
33. Targeted
Pretze M; van der Meulen NP; Wängler C; Schibli R; Wängler B
J Labelled Comp Radiopharm; 2019 Jun; 62(8):471-482. PubMed ID: 30980411
[TBL] [Abstract][Full Text] [Related]
34. Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery.
Chakravarty R; Goel S; Hong H; Chen F; Valdovinos HF; Hernandez R; Barnhart TE; Cai W
Nanomedicine (Lond); 2015; 10(8):1233-46. PubMed ID: 25955122
[TBL] [Abstract][Full Text] [Related]
35. pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer.
Wan X; Liu C; Lin Y; Fu J; Lu G; Lu Z
Drug Deliv; 2019 Dec; 26(1):470-480. PubMed ID: 30957572
[TBL] [Abstract][Full Text] [Related]
36.
Chakravarty R; Chakraborty S; Dash A
Mol Pharm; 2016 Nov; 13(11):3601-3612. PubMed ID: 27709959
[TBL] [Abstract][Full Text] [Related]
37. Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer.
Chen F; Ma K; Madajewski B; Zhuang L; Zhang L; Rickert K; Marelli M; Yoo B; Turker MZ; Overholtzer M; Quinn TP; Gonen M; Zanzonico P; Tuesca A; Bowen MA; Norton L; Subramony JA; Wiesner U; Bradbury MS
Nat Commun; 2018 Oct; 9(1):4141. PubMed ID: 30297810
[TBL] [Abstract][Full Text] [Related]
38. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
[TBL] [Abstract][Full Text] [Related]
39. A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.
Lee H; Zheng J; Gaddy D; Orcutt KD; Leonard S; Geretti E; Hesterman J; Harwell C; Hoppin J; Jaffray DA; Wickham T; Hendriks BS; Kirpotin D
Nanomedicine; 2015 Jan; 11(1):155-65. PubMed ID: 25200610
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of a
Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
